Announcements Trials
Browse Landscape

Status

No longer available 4Approved for marketing 1

Sponsor Class

OTHER 5INDUSTRY 4FED 1

Study Type

Expanded_access 5

Sponsor

Conditions

Lambert-Eaton Myasthenic Syndrome 5Myasthenic Syndromes, Congenital 2Myasthenia Gravis 1

Interventions

Amifampridine 5thymoglobulin 1prednylidene 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Walk Test 1Prednisone 1Physical Therapy Modalities 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Etoposide 1Cytarabine 1Carmustine 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Lambert-Eaton Myasthenic Syndrome × Amifampridine × Clear all
NCT00872950 2022-04-11

LEMS

Lahey Clinic

Approved for marketing

Lambert-Eaton Myasthenic Syndrome, Myasthenic Syndromes, Congenital

NCT02012933 2019-12-11

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

Oregon Health and Science University

No longer available

Lambert-Eaton Myasthenic Syndrome, Myasthenic Syndromes, Congenital

NCT00704925 2019-10-30

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

University of California, Davis

No longer available

Lambert-Eaton Myasthenic Syndrome

NCT00994916 2019-07-09

Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

University of Pittsburgh

No longer available

Lambert-Eaton Myasthenic Syndrome

NCT01378546 2013-07-18

Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

Columbia University

No longer available

Lambert-Eaton Myasthenic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡